StemCell Therapy

The innate immune system is full of targets that could be harnessed against diseases from cancer to lupus to epilepsy. But researchers have struggled to hit them because they didnt know the structure of those targets.

We didnt know the confirmation [of the targets], where the pockets are, how big they are, Marcelo Bigal, CEO of Ventus Therapeutics, told FierceBiotech. Which means trying to develop a drug against something you dont seeits drug development with the lights off.

With its structural immunology technology, Ventus is switching the lights on, emerging from stealth with $60 million from Versant Ventures and GV to advance three programs. The company is developing multiple small molecules against each of the three targets but is keeping specific disease areas under wraps, Bigal said.

Maintaining Momentum: Applying Recent Regulatory Guidance in the Midst of the Coronavirus

A panel of CATO SMS experts will review the key issues contained in the emerging Agency Guidance and offer thoughts on what changes and options for sponsors may be seen in the coming months.

RELATED: Quench Bio emerges with $50M to treat severe inflammatory diseases

The company is working to inhibit the targets, which could be useful in several areas including brain, immune and cardiometabolic disorders as well as monogenic diseases, in which a genetic mutation causes the body to make too much of a disease-causing protein. But its also looking to stimulate those targets, which could come in handy fighting cancer.

Ventus pipeline aims at two main pathways of the innate immune system: the inflammasome and the DNA-sensing pathway, also called the interferon pathway. They form the bodys first line of defense, sensing danger within cells and sacrificing those cells to contain the threat, Bigal said. The companys platform does more than elucidate protein structureit also surmounts problems scientists have faced when trying to drug the targets in a lab dish.

RELATED: IFM gets new CEO, bags another $55M to launch incubator, new subsidiaries

The targets exist as monomers, or small pieces of proteins, inside cells until they sense a threat. In response, theyll assemble into a larger protein, Bigal said.

But when you put monomers in vitro to do drug development, they immediately oligomerize and become this very large chunk of protein that nobody can handle, he said. With Ventus technology, its scientists can purify and immobilize these proteins, so they can study drugs in vitro before moving on to animal studies, where in the past, they would have gone straight to animal studies in a trial-and-error approach.

Ventus three programs are fully funded through meaningful inflection points, but Ventus has nine other targets that its not actively working on, Bigal said. All 12 offer partnership opportunities, whether a partner is interested in pursuing its three selected targets in other disease areas or in a target-based, disease area-based or platform-wide partnership.

Because we are well-funded, that means in the next month, its pipeline, pipeline, pipeline But meanwhile, we are allowing ourselves to have very selective conversations with pharma to foster possibilities for a quality partnership, Bigal said.

The company, which is based in Boston and Montreal, plans to grow to more than 30 scientists this year.

Follow this link:
Ventus uncloaks with $60M to chase targets in the innate immune system - FierceBiotech

This entry was posted on May 8, 2020 at 2:46 pm and is filed under Immune System. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |